Patent ID: 11951163
Assignee: VALNEVA AUSTRIA GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 0:
1. A Zika virus vaccine comprising a Zika virus having an RNA genome corresponding to the DNA sequence provided by SEQ ID NO: 4 or a variant nucleic acid having at least 99% identity to SEQ ID NO: 4, wherein the sequence identity is determined by Needleman-Wunsch homology alignment, wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects, wherein the neutralizing antibody titer is determined using a microneutralization assay (MN50) following a single administration of the Zika virus vaccine to a subject;
wherein the Zika virus comprises an E protein having an amino acid sequence provided by SEQ ID NO: 47; and
wherein the Zika virus is Vero cell adapted and is able to pack a virulent Zika virus.